Chen Yaojia, Gong Yuxin, Dou Lijun, Zhou Xun, Zhang Ying
Yangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou, China.
Yangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou, China; School of Mathematics and Statistics, Hainan Normal University, Haikou, China.
Comput Biol Med. 2022 Apr;143:105283. doi: 10.1016/j.compbiomed.2022.105283. Epub 2022 Feb 3.
As a kind of novel non-invasive marker for molecular detection, cell-free DNA (cfDNA) has potential value for the early diagnosis of diseases, prognosis assessment, and efficacy monitoring. The constant developments in molecular biology detection technologies have led to an increase in clinical studies on the use of cfDNA detection methods for patients, and many gratifying outcomes have been achieved. In this review, the contributions of bioinformatics tools to the study of cfDNA are well discussed. The focus of the review is on cfDNA identification signals, cfDNA identification methods, and the relationship of cfDNA with human diseases such as hepatic cancer, lung cancer, end-stage kidney disease, and ischemic stroke. The research significance and existing problems of using cfDNA as a biomarker for diseases are also discussed.
作为一种用于分子检测的新型非侵入性标志物，游离DNA（cfDNA）在疾病的早期诊断、预后评估和疗效监测方面具有潜在价值。分子生物学检测技术的不断发展使得针对患者使用cfDNA检测方法的临床研究不断增加，并取得了许多令人满意的成果。在这篇综述中，对生物信息学工具在cfDNA研究中的贡献进行了充分讨论。该综述的重点在于cfDNA识别信号、cfDNA识别方法以及cfDNA与肝癌、肺癌、终末期肾病和缺血性中风等人类疾病的关系。还讨论了将cfDNA用作疾病生物标志物的研究意义和存在的问题。
